Alzheimer’s drug review questions whether new treatments work

LONDON: Serious doubts have been cast over the efficacy of a new wave of drugs to treat Alzheimer’s disease, with a leading international scientific review concluding the drugs offer patients only “trivial” improvement compared with a placebo, but carry significant safety risks.

Dementia is now Australia’s leading cause of death and Alzheimer’s is the most common form of the disease. Yet, for all the demand, breakthroughs in meaningful treatments have been limited, leaving patients and their loved ones devastated.

That all changed in 2025 when a new class of disease-modifying drugs was approved for use. They were the first new Alzheimer’s drugs in 25 years and work by clearing the brain of amyloid plaque. The idea was that they could help slow early-stage progression of Alzheimer’s, and early studies suggested the delaying effect could be between six weeks and a few months.

Now the conclusions of a Cochrane review suggest those benefits may be less significant than first hoped.

“Unfortunately, the evidence suggests that these drugs make no meaningful difference to patients,” said lead author Francesco Nonino, a neurologist and epidemiologist at the IRCCS Institute of Neurological Sciences of Bologna in Italy.

While the drugs do help to remove amyloid proteins from the brain, reviewers found this did not translate into meaningful clinical benefits for patients.

In a statement, the reviewers said: “The absolute effects of anti-amyloid drugs on cognitive decline and dementia severity were absent or trivial, falling well below established thresholds for the minimum clinically important difference.”

Dr Nonino said the findings were important.

“There is now a convincing body of evidence converging on the conclusion that there is no clinically meaningful effect,” he said. “While early trials showed results that were statistically significant, it is important to distinguish between this and clinical relevance.”

For the Cochrane review, considered the gold standard in scientific and medical reviews and used to inform health policy, researchers analysed 17 existing studies that assessed seven types of amyloid-beta-targeting monoclonal antibodies including lecanemab and donanemab; the two drugs available in Australia.

The reviewers said concerns remained about side-effects of the drugs.

“Anti-amyloid monoclonal antibodies probably cause more brain swelling and tiny (micro) bleeds than placebo,” they said.

The inclusion of the seven medications has faced some criticism because it includes older medications that did not share results as positive as the more recent two.

“Only two of the 17 studies include the drugs that are currently registered in Australia. So I think that lumping together a whole lot of drugs that didn’t work with two that did … is of concern,” Dementia Australia honorary medical adviser Michael Woodward said.

“Unfortunately, the nay-sayers are going to say this Cochrane review proves that these drugs don’t work, but my belief is that those two drugs do work, and that’s why the (government) has registered them.

“Let’s say we did a meta-analysis of all cancer therapies that have ever been tried for breast cancer and we know that some of those didn’t work. If the meta-analysis shows that when you put all the trials in, including drugs that were found to not work, and came up with the conclusion that treatment for breast cancer is only mildly effective, would you stop treating people for breast cancer with effective drugs?”

Professor Woodward said six ongoing amyloid-targeting drug studies could change future analysis, showing greater efficacy as understanding of treatments improved. He acknowledged his role in clinical trials funded by drug companies behind amyloid treatments represented a conflict of interest but did not believe it warped his judgment.

Lilly, the pharmaceutical sponsor of donanemab, also criticised the method of the study, saying medications are not approved based on pool data, but individual results.

“The Cochrane review is built on an inherently flawed methodology,” a spokesman for Lilly Australia said. “It pools data across multiple amyloid-targeting therapies as a class, including molecules that did not achieve their clinical trial endpoints and were never granted regulatory approval.

“Combining data on unsuccessful molecules with approved medicines artificially dilutes the observed benefit – and produces class-level conclusions that do not reflect the evidence for any individual approved therapy.”

Bryce Vissel is a neuroscientist who specialises in Alzheimer’s disease and a professor of neuroscience at the University of NSW. He has long been cautious about the hype surrounding anti-amyloid medications and believes this review shows why that caution is needed.

“This review does not prove amyloid has no role in Alzheimer’s and it does not rule out future amyloid-directed therapies that may yet help patients,” Professor Vissel said. “But it does show that the current generation of anti-amyloid drugs is not delivering the promise that has surrounded it.”

While lecanemab and donanemab were eventually approved for use in Australia in 2025, after some pushback, they have been rejected from inclusion on the Pharmaceutical Benefits Scheme because their proven benefits are limited and they carry serious potential side-effects including brain swelling and bleeding, which health authorities said did not justify their hefty costs.

As a result, patients wanting to take the drugs need to pay tens of thousands of dollars to do so. Previous reporting by The Australian has found that a course of treatment may cost more than $120,000. The drugs are delivered by fortnightly or monthly infusion, which are given to patients in-clinic.

More recently, clinicians have been hopeful new studies – still being conducted – will show the drugs mean patients can live with earlier stages of the disease for longer. While that may still be proven, this review – which takes a broader look at a wide variety of evidence – comes as a blow.

It also reignites an old debate about the role of amyloid plaque in Alzheimer’s disease. People with the disease have been shown to have higher levels of the amyloid-beta protein.

Amyloid brain plaques were first recognised in 1991 and were theorised to have a direct consequence on memory in a 2006 Nature study that laid the groundwork for decades of further research. Years later, the study was found to be based on falsified data and was retracted.

However, the amyloid hypothesis as a whole is not invalidated. Sections of the scientific community suggest amyloid and tau protein should be considered with equal weight to other factors such as blood vessel health, inflammation, immune dysfunction and protein deficiencies.

Beyond lecanemab and donanemab, treatment options are scarce. Drugs known as cholinesterase inhibitors can be prescribed for mild to moderate Alzheimer’s symptoms. Most other treatments are used to handle the emotional, psychological or pain symptoms of dementia but do not delay disease progression.

That’s why so much excitement has grown around this new wave of drugs.

For years, Professor Vissel has rallied against the intense focus on the amyloid theory.

“We have long argued that while amyloid has a role in the disease, it alone does not explain Alzheimer’s dementia and a new way forward is needed,” he said.

He worries the theory is distracting and could delay the discovery of more meaningful therapies.

“The way forward is to widen the lens: focus on the molecular and cellular biology of what is going wrong inside vulnerable brain cells and synapses, and develop genuinely individualised treatments judged by meaningful gains in cognition, daily function and independence. This is the approach our team is taking,” he said.

“No patient can derive benefit from plaque clearance unless it translates into tangible improvements in quality of life. Until we identify and target root disease causes and achieve profound clinical benefit, no therapy can be called disease-modifying.

“This Cochrane review forces a blunt question: If these drugs remove the very plaques long thought to drive Alzheimer’s, why are patients not getting a meaningful improvement in memory, thinking, daily function or independence?”

While Cochrane reviews are considered to be the highest standard of evidence-based medicine, they can come with flaws. In this instance, reviewers say their confidence in the evidence is limited and their conclusions may change in the future based on new evidence.

“Our confidence in the evidence is limited for two reasons,” the authors write.

“Firstly, people who received monoclonal antibodies had more brain swelling and microbleeds than people receiving placebo.

“However, most studies did not separate people with symptoms of brain swelling and microbleeds from those in whom these effects were only visible with a scan.

“This reporting gap leaves patients without the information they need to understand the seriousness of potential unwanted effects.

“Secondly, the results came from studies that did not last very long. These are important limitations in the evidence for people with Alzheimer’s disease, who need to know the longer-term benefits and unwanted effects of medicines.”